Trial reportScientific reports2025
Pistacia atlantica can improve oxidative status in patients with metabolic dysfunction-associated fatty liver disease.
Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a problem worldwide. Oxidative stress is important factor in beginning and progress of MAFLD. This study is the first clinical trial with the aim of determining the effect of Pistacia atlantica Sub. Kurdica gum on oxidative status in patients with metabolic dysfunction-associated fatty liver disease. In this double-blind randomized clinical trial 50 patients with metabolic dysfunction-associated fatty liver disease were randomized into two groups: those given syrup containing Pistacia atlantica sub. Kurdica gum (Group A), those on placebo (Group B). Over a two-month period, Group A given syrup containing 500 mg of P. atlantica sub. Kurdica gum per each tablespoon and Group B given syrup without P. atlantica sub. Kurdica gum. Anthropometric measures, serum oxidative markers and physical activity were evaluated at the beginning and end of the intervention. We observed a significant decrease in fatty liver grade in group A (P = 0.03). In the end of intervention had not been show significant change in serum total antioxidant capacity (TOS) in group A (P = 0.91) and group B (0.70). Serum total oxidant status (TAC) had been show increase in group A and decrease in group B but this changes not significant as within group (P = 0.36, P = 0.53, respectively) and between group (P = 0.66). The mean of Malondialdehid (MDA) had significant decrease from baseline in group A (P = 0.002) and had non-significant increase in group B (P = 0.65). The between-group comparison of changes of MDA had been show a significant difference (P = 0.025). As well as, after adjusting for baseline characteristics (Age, Gender, Physical activity, BMI), there were not significant differences between A and B groups in the changes comparison of TOS and TAC except for MDA (p < 0.032). Weight had significant decrease in group A (P = 0 < 001). Pistacia atlantica sub. Kurdica gum can improve some oxidative status indices, particularly lipid peroxidation and subsequently MAFLD in patient with metabolic dysfunction-associated fatty liver disease, but further studies with larger samples, longer duration and dose-response assessment will be needed.Trial registration: IRCT20231219060466N1, 2024-01-05 (https//irct.behdasht.gov.ir/).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.